Nektar Therapeutics (NKTR)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Nektar Therapeutics (NKTR)
Go deeper and ask any question about NKTR
Company Performance
Current Price
as of Sep 13, 2024$1.31
P/E Ratio
N/A
Market Cap
$241.14M
Description
Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes therapies for oncology, immunology and virology. The firm focuses on using new chemistry approaches to make medicines to treat cancer and autoimmune diseases. The company was founded in 1990 and is headquartered in San Francisco, CA.
Metrics
Overview
- HQSan Francisco, CA
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerNKTR
- Price$1.31+4.80%
Trading Information
- Market Cap$241.14M
- Float96.60%
- Average Daily Volume (1m)804,389
- Average Daily Volume (3m)1,559,908
- EPS-$0.90
Company
- Revenue$93.16M
- Rev Growth (1yr)14.59%
- Net Income-$52.36M
- Gross Margin58.53%
- EBITDA Margin-149.12%
- EBITDA-$35.03M
- EV$207.32M
- EV/Revenue2.23
- P/EN/A
- P/S2.94
Documents
SEC Filings
Earnings Calls
Factset Street Account
Wikipedia